Form 4: Theravance Biopharma CEO Gifts 20,000 Shares in Latest SEC Filing

Theravance Biopharma, Inc. CEO Rick E. Winningham reported gifting 20,000 ordinary shares, a transaction filed with the SEC on June 25, 2025.

Summary

• Rick E. Winningham, the Chief Executive Officer and a Director of Theravance Biopharma, Inc. (TBPH), reported a disposition of 20,000 ordinary shares.
• The transaction, which occurred on June 23, 2025, was classified as a bona fide gift, meaning no compensation was received by Mr. Winningham for the shares.
• Following this transaction, Mr. Winningham's direct beneficial ownership stands at 1,733,180 ordinary shares.
• Additionally, he indirectly beneficially owns 13,500 ordinary shares as custodian and 92,567 ordinary shares through a trust.

Sentiment

Score: 5

Explanation: The filing reports a gift of shares by the CEO, which is a neutral event in terms of company operations and financial health. It does not indicate a sale for liquidity or a lack of confidence, but rather a personal disposition.

Positives

• The transaction was a gift, indicating that the CEO did not sell shares for personal liquidity, which can be viewed as a neutral to slightly positive signal regarding his confidence in the company's long-term prospects.

Negatives

• The direct beneficial ownership of ordinary shares by the CEO decreased by 20,000 shares.

Risks

• No specific risks related to the company's operations or financial health are identified in this Form 4 filing, as it pertains solely to an insider transaction.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• The disposition of 20,000 ordinary shares by Rick E. Winningham was a bona fide gift, implying a transaction with a related party (e.g., family member or trust) without compensation.

Stakeholder Impact

• Shareholders: The transaction represents a minor change in the CEO's direct beneficial ownership, but the shares remain within a related party, suggesting continued alignment of interests.

Key Dates

Keywords

Theravance Biopharma, TBPH, SEC Form 4, Insider Transaction, Share Gift, Rick E. Winningham, CEO, Beneficial Ownership